Literature DB >> 3029790

Impaired growth hormone response to sodium valproate in normal aging.

P Monteleone, M Iovino, F Orio, L Steardo.   

Abstract

Evidence has been provided for impaired neurotransmitter functioning in the brain of elderly subjects. In order to assess central GABAergic transmission, the activity of the hypothalamic GABA system may be investigated by basal growth hormone (GH) response to the GABAergic drug sodium valproate (SV). For this purpose 15 healthy men (aged 19-81 years) received orally 800 mg SV or placebo tablets on two different occasions, 1 week apart. Blood samples were collected before and after drug administration for determining GH and SV plasma levels. A clear-cut increase in plasma GH was observed following SV (P less than 0.001 in young persons, P less than 0.005 in old subjects), but in the aged subjects this rise was statistically lower than in the young men (P less than 0.001 at t = 90 min). No difference was observed in basal GH levels and in SV plasma concentrations between elderly and young subjects. delta GH (= maximum post-SV GH level minus baseline GH value) was significantly inversely related to age (r = -0.90, P less than 0.001). These results may suggest an impaired hypothalamic-pituitary responsiveness to a pharmacological challenge enhancing endogenous GABA tone in the elderly.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3029790     DOI: 10.1007/BF00690918

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  23 in total

1.  Pharmacological evidence for a dual GABAergic regulation of growth hormone release in humans.

Authors:  L Steardo; M Iovino; P Monteleone; M Agrusta; F Orio
Journal:  Life Sci       Date:  1986-09-15       Impact factor: 5.037

2.  Growth hormone response to sodium valproate in chronic schizophrenia.

Authors:  P Monteleone; M Maj; M Iovino; L Steardo
Journal:  Biol Psychiatry       Date:  1986-06       Impact factor: 13.382

3.  Effects of DI-n-propylacetate, and anticonvulsive compound, on GABA metabolism.

Authors:  Y Godin; L Heiner; J Mark; P Mandel
Journal:  J Neurochem       Date:  1969-06       Impact factor: 5.372

Review 4.  Regulatory role of gamma-aminobutyric acid in pituitary hormone secretion.

Authors:  A N Elias; L J Valenta; A V Szekeres; M K Grossman
Journal:  Psychoneuroendocrinology       Date:  1982       Impact factor: 4.905

5.  Effects of intraventricular injection of gamma-aminobutyric acid (GABA) on plasma growth hormone and thyrotropin in conscious ovariectomized rats.

Authors:  E Vijayan; S M McCann
Journal:  Endocrinology       Date:  1978-11       Impact factor: 4.736

6.  Effects of some gamma-aminobutyric acid (GABA)-ergic drugs on the dopaminergic control of human growth hormone secretion.

Authors:  M Koulu; R Lammintausta; S Dahlström
Journal:  J Clin Endocrinol Metab       Date:  1980-07       Impact factor: 5.958

7.  Site of gamma-aminobutyric acid (GABA)-mediated inhibition of growth hormone secretion in the rat.

Authors:  J Fiók; Z Acs; G B Makara; S L Erdö
Journal:  Neuroendocrinology       Date:  1984-12       Impact factor: 4.914

8.  Concomitant increases in serum growth hormone and hypothalamic somatostatin in rats after injection of gamma-aminobutyric acid, aminooxyacetic acid, or gamma-hydroxybutyric acid.

Authors:  J Takahara; S Yunoki; H Hosogi; W Yakushiji; J Kageyama; T Ofuji
Journal:  Endocrinology       Date:  1980-01       Impact factor: 4.736

9.  Characterization of rat hypothalamic growth hormone-releasing factor.

Authors:  J Spiess; J Rivier; W Vale
Journal:  Nature       Date:  1983 Jun 9-15       Impact factor: 49.962

10.  Stimulatory effects of gamma-hydroxybutyric acid on growth hormone and prolactin release in humans.

Authors:  J Takahara; S Yunoki; W Yakushiji; J Yamauchi; Y Yamane
Journal:  J Clin Endocrinol Metab       Date:  1977-05       Impact factor: 5.958

View more
  1 in total

1.  Increased sensitivity to the anticonvulsant effect of valproate in aging BN/BiRij rats.

Authors:  A M Stijnen; S Hovinga; M W Langemeijer; A Hoogerkamp; C F van Bezooijen; M Danhof
Journal:  Pharm Res       Date:  1993-07       Impact factor: 4.200

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.